Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate

Saint Herblain (France), May 25, 2022– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials